Psoriasiform Eruption Induced by Infliximab
- 1 January 2004
- journal article
- case report
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (1) , 54-57
- https://doi.org/10.1345/aph.1c477
Abstract
OBJECTIVE: To report a case of psoriasiform eruption induced by infliximab. CASE SUMMARY: A 46-year-old woman with enterocutaneous fistula secondary to Crohn's disease developed pruriginous, erythematous, desquamative plaques on her elbows, knees, hands, and buttocks after receiving the second and third doses of intravenous infliximab. Histologic examination showed a lichenoid pattern. No new cutaneous lesions appeared after cessation of infliximab therapy. DISCUSSION: Several cutaneous reactions secondary to infliximab, a monoclonal antibody against tumor necrosis factor-alfa, have been described. Psoriasiform dermatitis has not been reported as a cutaneous reaction to infliximab, but there have been several previous reports of psoriasiform dermatitis secondary to other drugs. An objective causality assessment revealed that the adverse event was probable. CONCLUSIONS: This is the first report of a clinico-pathologic dissociated pattern of cutaneous reaction showing a histopathologic picture of lichenoid dermatitis resulting from infliximab treatment.Keywords
This publication has 23 references indexed in Scilit:
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- TARGETING TUMOUR NECROSIS FACTOR ALPHADermatologic Clinics, 2001
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Severe anaphylactic reaction to infliximab: report of a caseAmerican Journal of Gastroenterology, 2000
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Antibodies to tumour necrosis factor α as treatment for Crohn's diseaseThe Lancet, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and SafetyInflammatory Bowel Diseases, 1999
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993